Elobixibat

Generic Name: Elobixibat

Drug Type: Small Molecule

Chemical Formula: C_₃₆H_₄₅N_₃O_₇S_₂

CAS Number: 439087-18-0

Unique Ingredient Identifier: 865UEK4EJC

Background: Elobixibat has been used in trials studying the treatment and basic science of Dyslipidemia, Constipation, Chronic Constipation, Functional Constipation, and Chronic Idiopathic Constipation.

Clinical Trials

Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen

Not Applicable

Recruiting

Conditions: Bowel Preparation Solution
Colonoscopy

Interventions: Drug: 2-Liter polyethylene glycol plus elobixibat
Drug: 4-Liter polyethylene glycol

First Posted Date: 2024-05-31

Last Posted Date: 2024-12-27

Lead Sponsor: Rajavithi Hospital

Target Recruit Count: 360

Registration Number: NCT06436833

Locations: 🇹🇭
Rajavithi Hospital, Bangkok, Thailand

Elobixibat for Chronic Constipation Without Defecation Desire

Phase 4

Terminated

Conditions: Chronic Constipation

Interventions: Drug: Elobixibat 10mg

First Posted Date: 2023-01-30

Last Posted Date: 2023-03-09

Lead Sponsor: International University of Health and Welfare

Target Recruit Count: 40

Registration Number: NCT05703464

Locations: 🇯🇵
International university health and welfare Narita hospital, Narita, Japan

Elobixibat for Chronic Constipation Without Defecation Desire

Phase 4

Conditions: Chronic Constipation

Interventions: Drug: Elobixibat 10mg

First Posted Date: 2021-12-21

Last Posted Date: 2022-03-23

Lead Sponsor: Yokohama City University

Target Recruit Count: 40

Registration Number: NCT05165199

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

Long-term Elobixibat for Chronic Constipation

Phase 4

Recruiting

Conditions: Chronic Constipation

Interventions: Drug: Elobixibat 10mg
Drug: Placebo

First Posted Date: 2021-03-05

Last Posted Date: 2023-01-05

Lead Sponsor: Yokohama City University

Target Recruit Count: 100

Registration Number: NCT04784780

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver

Interventions: Drug: Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
Drug: Elobixibat placebo + cholestyramine powder placebo
Drug: Elobixibat 10mg + cholestyramine powder placebo
Drug: Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)

First Posted Date: 2020-01-21

Last Posted Date: 2021-11-16

Lead Sponsor: Yokohama City University

Target Recruit Count: 102

Registration Number: NCT04235205

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Phase 2

Completed

Conditions: NAFLD
NASH

Interventions: Drug: Placebo oral tablet
Drug: Elobixibat

First Posted Date: 2019-07-05

Last Posted Date: 2021-09-27

Lead Sponsor: Albireo

Target Recruit Count: 47

Registration Number: NCT04006145

Locations: 🇺🇸
Integrity Clinical Research, LLC, Doral, Florida, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States

and more 7 locations

Elobixibat Colonic Motor Function Study

Phase 2

Withdrawn

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: placebo
Drug: elobixibat

First Posted Date: 2015-03-19

Last Posted Date: 2015-06-03

Lead Sponsor: Ferring Pharmaceuticals

Registration Number: NCT02392546

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

Phase 3

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Elobixibat 10 mg

First Posted Date: 2013-07-10

Last Posted Date: 2016-05-09

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 411

Registration Number: NCT01895543

Locations: 🇺🇸
Meridien Research, Bradenton, Florida, United States
🇨🇦
Prime Health Clinical Research Organization (there may be other sites in this country), Toronto, Ontario, Canada
🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States

and more 57 locations

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Phase 3

Terminated

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Elobixibat 5 mg/day
Drug: Elobixibat 10 mg/day
Drug: Placebo

First Posted Date: 2013-04-16

Last Posted Date: 2015-10-20

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 314

Registration Number: NCT01833065

Locations: 🇺🇸
David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Zasa Clinical Research, Boynton Beach, Florida, United States
🇺🇸
Meridien Research, Bradenton, Florida, United States

and more 89 locations

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Phase 3

Terminated

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Elobixibat 5 mg
Drug: Elobixibat 10 mg
Drug: Placebo

First Posted Date: 2013-04-09

Last Posted Date: 2015-10-20

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 376

Registration Number: NCT01827592

Locations: 🇧🇪
Huisartspraktijk Jaak Mortelmans, Ham, Belgium
🇺🇸
ActivMed Practices and Research, Inc., Newington, New Hampshire, United States
🇮🇱
Sheba Medical Center, Tel Hashomer, Israel

and more 87 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy